Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-08
2009-12-29
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S321000, C514S322000
Reexamination Certificate
active
07638534
ABSTRACT:
Use of a compound of formula (I), wherein X is CH or N, and when X is CH, R is H, OH, a linear or branched alkyl chain having from 1 to 3 carbon atoms, a linear or branched alkoxy chain having from 1 to 3 carbon atoms, or a halogen atom, and when X is N, R is H, or an acid addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, to prepare a pharmaceutical composition active in the treatment of neuropathic pain.
REFERENCES:
patent: 5817676 (1998-10-01), Catlow et al.
patent: 6624162 (2003-09-01), Uchida et al.
patent: 2006/0052417 (2006-03-01), Alisi et al.
patent: 0 884 319 (1998-12-01), None
patent: 0 630 376 (1999-06-01), None
patent: 0 975 623 (2000-02-01), None
patent: 93/03725 (1993-03-01), None
patent: 93/06108 (1993-04-01), None
patent: 2004/014922 (2004-02-01), None
Pain and Nociception, Wikipedia, p. 1-7.
Pain and Nociception, Wikipedia, p. 1-7, 2007.
Doak, G.J.; Sawynok, J.: “Formalin-Induced Nociceptive Behavior and Edema: Invovlement of Multiple Peripheral 5-Hydroxytryptamine Receptor Subtypes” Neurosience, vol. 80, No. 3, 1997, pp. 939-949, XP002279566.
Donahue, et al.; “Electrolytic Lesion of the Anterior Cingulate Cortex Decreases Inflammatory, but not Neuropathic Nociceptive Behavior in Rats” Brain Research, vol. 897, No. 1-2, 2001, pp. 131-138, XP002279567.
Beers, M. and Berkow, R.: “The Merck Manual of Diagnosis and Therapy, Seventeenth Edition” 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002279568, p. 1371-1372.
Espejoe, et al.: “Antagonism of Peripheral 5-HT4 Receptors Reduces Visceral and Cutaneous Pain in Mice, and Induces Visceral Analgsia After Simultaneous Inactivation f 5-HT3 Receptors” Brain Research, Amsterdam, NL; vol. 788, No. 1/2, 1998, pp. 20-24 XP001064161.
Torssell, Kurt et al., “Isolation, Structure and Synthesis of Alkaloids From Valeriana Officinalis L”, Acta Chemica Scandinavica 21 (1), pp. 53-62, 1967.
Ashburn, Michael A., Staats, Peter S.: “Management of Chronic Pain”, The Lancet, vol. 353, pp. 1865-1869, 1999.
Bannon, A.W., et al.: “ABT-594, a novel cholinergic channel modulator is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain”Brain Research, vol. 801, pp. 158-163, 1998.
Bennett, Gary J. and Xie, Y.K.: “A Peripheral Mononeuropathy in Rat that Produces Disorders of Pain Sensation Like Those Seen in Man”, Pain, 33, pp. 87-107, 1988.
Courteix, C., Eschalier, A., and Lavarenne, J.: “Streptozocin-Induced Diabetic Rats: Behavioural Evidence for a Model of Chronic Pain”, Pain, 53, pp. 81-88, 1993.
Scholz, J. and Woolf, C.J.: “Can We Conquer Pain?”, Nature Neuroscience, vol. 5, pp. 1062-1067, Nov. 2002.
Seltzer, Z. et al.: “A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury”, Pain, 43, pp. 205-218, 1990.
Woolf, CLifford J. et al.: “Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management”, The Lancet, vol. 353, pp. 1959-1964, Jun. 5, 1999.
U.S. Appl. No. 10/549,930, filed Sep. 20, 2005, Alisi, et al.
U.S. Appl. No. 10/560,836, filed Dec. 15, 2005, Guglielmotti, et al.
Houghton et al. “5-HT4receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit”, Aliment Pharmacol Ther, vol. 13, pp. 1437-1444, 1999.
Wei et al. “Influence of Two Serotonin Receptor Antagonists in Neuropathic Rats”, Pfluegers Archiv European Journal of Physiology, vol. 443, No. supplement 1, p. S181, 2002.
Smith, M.I., et al., “5-HT4receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3receptor antagonism in conscious rats” Neuroscience Letters 271 (1999) , pp. 61-64.
Jorum E., et al., “Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine—a double-blind, cross-over comparison with alfentanil and placebo”, Pain 101 (2003) pp. 229-235.
Burstein R., et al., “The development of cutaneous allodynia during a migraine attack—Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine”, Brain (2000), 123, pp. 1703-1709.
Neuropathic pain causes, symptoms, diagnosis, and treatments on MedicineNet.com, Pain Management: Neuropathic Pain (3 pages), 2008.
Dorlands Medical Dictionary, Dorland's Illustrated Medical Dictionary (22 pages), 2008.
Abdominal Pain Causes, Symptoms, Diagnosis and Treatment by MedicineNet.com, Abdominal Pain Index (3 pages), 2008.
Allodynia—Wikipedia, the free encyclopedia, Allodynia (5 pages), 2008.
Pain and nociception—Wikipedia, the free encyclopedia, Pain and nociception (7 pages), 2007.
Hyperalgesia—Wikipedia, the free encyclopedia , Hyperalgesia (1 page), 2007.
Migraine—Wikipedia, the free encyclopedia, Migraine (8 pages), 2007.
Medical Hypotheses -Elsevier, Guide for Authors (4 pages), 2008.
Omoigui S., The biochemical origin of pain—Proposing a new law of pain: The origin of all pain is imflammation and the inflammatory response. Part 1 of 3—A unifying law of pain, Medical Hypotheses, vol. 69, Issue 1 (13 pages), 2006.
Omoigui S., “The biochemical origin of pain: The origin of all pain is inflammation and the inflammatory response. Part 2 of 3—Inflammatory profile of pain syndromes”. Medical Hypotheses (13 pages), 2007.
Hill R., “NK1(substance P) receptor antagonists—why are they not analgesic in humans?”, Viewpoint, Trends in Pharmacological Sciences, Jul. 2000, vol. 21 (3 pages).
Ahmed M. , et al. “Management Strategies for the Treatment of Neuropathic Pain in the Elderly”, Drugs Aging, 2002:19(12), pp. 929-945.
Sadosky, A., et al., “A Review of the Epidemiology of Painful Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, and Less Commonly Studied Neuropathic Pain Conditions”, Pain Practice, vol. 8, Issue 1, 2008 pp. 45-56.
Do, Katheirne E. Galluzzi, “Managing Neuropathic Pain”, JAOA, Supplemental 6, vol. 107. No. 11, Nov. 2007.
Paice, J. A., “Mechanisms and Management of Neuropathic Pain in Cancer”, The Journal of Supportive Oncology, vol. 1, No. 2, Jul./Aug. 2003 pp. 107-120.
Veves, A., et al., “Painful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options”, Pain Medicine, vol. 9, No. 6, 2008, pp. 660-674.
Verma, S., et al., “HIV-Associated Neuropathic Pain, Epidemiology, Pathophysiology and Management”, CNS Drugs, 2005, 19 (4), pp. 325-334.
Tremont-Lukats,I.W., et al., “Anticonvulsants for Neuropathic Pain Syndromes—Mechanisms of Action and Place in Therapy”, Drugs, Nov. 2000, 60 (5), pp. 1029-1052.
Gray P. , “Acute neuropathic pain: diagnosis and treatment”, Current Opinion in Anaesthesiology, 2008, 21, pp. 590-595.
Finnerup, N. B, “A review of central neuropathic pain states”, Current Opinion in Anaesthesiology, 2008, 21, pp. 586-589.
Alisi Alessandra
Cazzolla Nicola
Guglielmotti Angelo
Polenzani Lorenzo
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Padmanabhan Sreeni
Ramachandran Umamaheswari
LandOfFree
Use of indazole derivatives for the treatment of neuropathic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of indazole derivatives for the treatment of neuropathic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of indazole derivatives for the treatment of neuropathic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111188